БИБЛИОТЕКА
-
- Фильтр
- Количество записей: 3194
-
- По дате
- По просмотрам
-
Зарубежные материалы
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study.
Подробнее922
-
Зарубежные материалы
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.
Подробнее896
-
Зарубежные материалы
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017
Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040
Подробнее858
-
Статьи
Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)
Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.
Подробнее1072
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее648
-
Зарубежные материалы
Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III)
End-stage renal disease is an important and costly health problem. Strategies for its prevention are urgently needed. Knowledge of the population-based prevalence of renal insufficiency in nondiabetic adults would inform such strategies.
Подробнее661
-
Зарубежные материалы
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
Подробнее638
-
Зарубежные материалы
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.
Подробнее769
-
Зарубежные материалы
Cardiorenal Syndrome
The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...
Подробнее826
-
Зарубежные материалы
2018 ESC/ESH Guidelines for the management of arterial hypertension
The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)
Подробнее791
-
Статьи
Артериальная гипертензия у взрослых
Артериальная гипертензия (АГ) — синдром повышения клинического артериального давления (АД) при гипертонической болезни и симптоматических АГ выше пороговых значений, определенных в результате эпидемиологических и рандомизированных контролируемых исследований, продемонстрировавших связь с повышением сердечнососудистого риска и целесообразность и пользу лечения, направленного на снижение АД ниже ...
Подробнее1072
-
Зарубежные материалы
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...
Подробнее799
-
Зарубежные материалы
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
Подробнее597
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...
Подробнее737
-
Зарубежные материалы
Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population
In 2015, more than 23 million adults in the United States had a diagnosis of diabetes, with an estimated 95% of cases being type 2 diabetes (T2D). Patients with T2D are at increased risk of cardiovascular disease (CVD),2 and therefore, improvement of cardiovascular (CV) outcomes is a goal of diabetes management.3,4 Good glycemic control in T2D has been associated with a reduced risk of microvascul ...
Подробнее747
- ← Предыдущая
- 1
- ...
- 82
- 83
- 84
- 85 (current)
- 86
- 87
- 88
- ...
- 213
- Следующая →